Pure Financial Advisors LLC Has $2.63 Million Position in Eli Lilly and Company (NYSE:LLY)

Pure Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 45.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,407 shares of the company’s stock after buying an additional 1,058 shares during the period. Pure Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $2,630,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Tudor Financial Inc. boosted its stake in shares of Eli Lilly and Company by 140.3% during the 4th quarter. Tudor Financial Inc. now owns 1,086 shares of the company’s stock valued at $839,000 after buying an additional 634 shares during the period. CMH Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 4.1% during the fourth quarter. CMH Wealth Management LLC now owns 13,872 shares of the company’s stock worth $10,709,000 after acquiring an additional 552 shares in the last quarter. Wealthquest Corp boosted its position in Eli Lilly and Company by 0.4% during the fourth quarter. Wealthquest Corp now owns 5,278 shares of the company’s stock valued at $4,075,000 after purchasing an additional 22 shares during the last quarter. Amplius Wealth Advisors LLC grew its stake in Eli Lilly and Company by 4.2% in the fourth quarter. Amplius Wealth Advisors LLC now owns 1,526 shares of the company’s stock valued at $1,178,000 after purchasing an additional 61 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its position in Eli Lilly and Company by 5.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 10,696 shares of the company’s stock worth $8,257,000 after purchasing an additional 546 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on LLY. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Bank of America reissued a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Citigroup raised their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Stock Up 1.5 %

LLY stock opened at $753.65 on Thursday. Eli Lilly and Company has a twelve month low of $614.82 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $715.46 billion, a PE ratio of 81.48, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41. The business’s 50-day simple moving average is $777.46 and its 200 day simple moving average is $851.61.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a share buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is presently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.